AtriCure (NASDAQ:ATRC) Issues Q1 2021 After-Hours Earnings Guidance


Share on StockTwits

AtriCure (NASDAQ:ATRC) updated its first quarter 2021
After-Hours earnings guidance on Tuesday. The company provided EPS guidance of -0.39–0.36 for the period, compared to the Thomson Reuters consensus EPS estimate of $-0.21. The company issued revenue guidance of $55-57 million, compared to the consensus revenue estimate of $59.31 million.AtriCure also updated its FY 2021
After-Hours guidance to -1.15–1.15 EPS.

A number of brokerages have recently issued reports on ATRC. Needham & Company LLC raised their target price on shares of AtriCure from $53.00 to $63.00 and gave the stock a buy rating in a research report on Friday, December 18th. Zacks Investment Research upgraded shares of AtriCure from a hold rating to a buy rating and set a $67.00 target price on the stock in a research report on Monday, February 8th. BTIG Research raised their target price on shares of AtriCure from $56.00 to $66.00 and gave the stock a buy rating in a research report on Thursday, January 21st. They noted that the move was a valuation call. SVB Leerink raised their target price on shares of AtriCure from $60.00 to $65.00 and gave the stock an outperform rating in a research report on Monday, December 14th. Finally, Piper Sandler raised their target price on shares of AtriCure from $50.00 to $66.00 and gave the stock an overweight rating in a research report on Friday, January 29th. Eight investment analysts have rated the stock with a buy rating, AtriCure presently has an average rating of Buy and an average price target of $60.13.

NASDAQ:ATRC traded down $2.97 during midday trading on Tuesday, reaching $62.24. The stock had a trading volume of 714,400 shares, compared to its average volume of 370,994. The firm has a fifty day simple moving average of $59.83 and a two-hundred day simple moving average of $47.08. AtriCure has a 12-month low of $23.17 and a 12-month high of $67.01. The company has a quick ratio of 5.85, a current ratio of 6.62 and a debt-to-equity ratio of 0.15. The stock has a market cap of $2.80 billion, a P/E ratio of -54.12 and a beta of 1.13.

In other AtriCure news, insider Salvatore Privitera sold 3,846 shares of the firm’s stock in a transaction on Wednesday, December 9th. The stock was sold at an average price of $47.50, for a total value of $182,685.00. Following the completion of the sale, the insider now owns 78,916 shares of the company’s stock, valued at $3,748,510. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, SVP Justin J. Noznesky sold 23,397 shares of the firm’s stock in a transaction on Monday, January 4th. The shares were sold at an average price of $53.58, for a total value of $1,253,611.26. Following the completion of the sale, the senior vice president now directly owns 66,005 shares of the company’s stock, valued at approximately $3,536,547.90. The disclosure for this sale can be found here. Over the last quarter, insiders sold 349,455 shares of company stock worth $20,101,556. 5.80% of the stock is currently owned by insiders.

AtriCure Company Profile

AtriCure, Inc develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems to medical centers in the United States and internationally. The company offers Isolator Synergy and Isolator Synergy Access clamps for the treatment of persistent and long-standing persistent atrial fibrillation concomitant to other open-heart surgical procedures; EPi-Sense guided coagulation system used for the coagulation of tissue; and COBRA Fusion surgical ablation system to combine bipolar temperature-controlled radio frequency energy control with monopolar energy.

See Also: What is Liquidity?

Earnings History and Estimates for AtriCure (NASDAQ:ATRC)

Receive News & Ratings for AtriCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure and related companies with MarketBeat.com's FREE daily email newsletter.